<DOC>
	<DOCNO>NCT02720003</DOCNO>
	<brief_summary>To assess safety efficacy BARD LTX DCB treatment stenosis occlusion superficial femoral popliteal artery .</brief_summary>
	<brief_title>A Single Arm Trial Evaluating BARD Lutonix Drug-Coated Balloon ( LTX DCB ) Treatment Femoropopliteal Arteries</brief_title>
	<detailed_description>The study enroll patient present claudication ischemic rest pain due stenotic lesion superficial femoral popliteal artery patent outflow artery foot . After successful pre-dilatation , subject determine investigator require stenting base defined angiographic criterion receive BARD LTX DCB . .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<criteria>Male female ≥18 &lt; 85 year age ; Documented diagnosis peripheral arterial disease ( PAD ) Rutherford Classification stag 24 ; Patient willing provide inform consent comply require follow visit , test schedule medication regimen ; Angiographic Criteria Single lesion two focal lesion ( separate &gt; 3 cm ) ( total vessel segment length ≤20 cm ) native superficial femoral and/or popliteal artery ; ≥70 % diameter stenosis visual estimate ; Lesion location start ≥1 cm common femoral bifurcation terminates distally ≤2 cm tibial plateau AND ≥1 cm origin TP trunk ; De novo lesion ( ) nonstented restenotic lesion ( ) &gt; 90 day prior angioplasty procedure ; Lesion locate least 3 cm stent , target vessel previously stented ; Target vessel diameter ≥4 ≤7 mm able treat available device size matrix ; Successful , uncomplicated ( without use cross device ) antegrade wire cross lesion ; A patent inflow artery free significant lesion ( ≥50 % stenosis ) confirm angiography ( treatment target lesion acceptable successful treatment inflow iliac and/or common femoral artery lesion ) ; No vascular intervention , surgical interventional procedure within 2 week and/or plan 30 day protocol treatment . Exclusion Criteria Patients exclude ANY follow condition apply : Breastfeeding pregnant plan become pregnant men intend father child ; Life expectancy &lt; 2 year ; Patient currently participate investigational drug device study previously enrol study ; History stroke within 3 month ; History MI , thrombolysis angina within 2 week enrollment ; Renal failure chronic kidney disease MDRD GFR ≤30 ml/min per 1.73 m2 ( serum creatinine ≥2.5 mg/dL within 30 day index procedure treat dialysis ) ; Diagnosed active systemic infection uncontrolled coagulopathy within 14 day prior index procedure Prior vascular surgery index limb , exception remote common femoral patch angioplasty separate least 2 cm target lesion ; Inability take require study medication allergy paclitaxel paclitaxel related compound contrast adequately manage pre postprocedure medication ; The lesion postDCB restenosis , within adjacent aneurysm ; Ipsilateral retrograde access ; There normal proximal arterial segment duplex flow velocity measure ; Known inadequate distal outflow ( ≥50 % stenosis distal popliteal and/or three tibial vessel ; ) , planned future treatment vascular disease distal target lesion ; Sudden symptom onset , acute vessel occlusion , acute subacute thrombus target vessel ; Severe calcification render lesion undilatable failed predilatation , define residual stenosis &gt; 50 % major flow limit dissection ; Use adjunctive treatment modality ( i.e . laser , atherectomy , cryoplasty , scoring/cutting balloon , embolic protection device , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>Superficial Femoral Artery</keyword>
	<keyword>Proximal Popliteal Artery</keyword>
</DOC>